Oncology

NICE recommends MSD’s pembrolizumab to treat melanoma

The UK National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (Keytruda) manufactured by MSD to treat melanoma, the most common form of skin cancer.

NeoImmuneTech receives Orphan Drug Designation for GBM therapy

NeoImmuneTech (NIT) has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for NT-I7 (efineptakin alfa) (rhIL-7-hyFc) to treat Glioblastoma Multiforme (GBM), one of the hardest-to-treat cancers.

Boehringer Ingelheim signs option to acquire Trutino Biosciences

Boehringer Ingelheim has signed an option to buy Trutino Biosciences, a San Diego-based biotech company.

NovoMedix gets NIH grant to advance NMX1 in TNBC

The National Heart, Lung, and Blood Institute division of the NIH has awarded biotechnology company NovoMedix a $2m Phase II SBIR grant to further the development of novel small molecules that protect patients with triple-negative breast cancer (TNBC) from the long-term cardiotoxic impacts of doxorubicin chemotherapy.

EMA grants orphan drug designation to Cornerstone Pharmaceuticals’ CPI-613 (devimistat)

Cornerstone Pharmaceuticals has announced that the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to CPI-613 (devimistat) to treat advanced unresectable biliary tract cancer.

Inceptor Bio raises $37m from Series A to advance CAR-T lead programme

Biotechnology firm Inceptor Bio has raised $37m from Series A funding round that was led by Kineticos Ventures.

Proteros expands oncology collaboration with AstraZeneca

Proteros biostructures has expanded its collaboration with AstraZeneca focused on the discovery and development of novel epigenetic drugs.

Moma Therapeutics completes funding for precision oncology programmes

Moma Therapeutics has completed a $150m Series B financing led by Goldman Sachs Asset Management for advancement of several precision oncology programmes to clinical trials.

InxMed raises funding to advance new cancer therapies

InxMed has raised $15m in Series B+ financing funded by Hyfinity Investments to advance new therapies for the treatment of drug-resistant cancers.